Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER/CDER Consolidation Receives McClellan’s Blessing; Tensions Continue

Executive Summary

Incoming Commissioner Mark McClellan, MD/PhD, is indicating strong support of the shift of biological product reviews from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research
Advertisement

Related Content

The Next Step In FDA Reform? Consolidated Drug/Device Groups Proposed By FOCR
CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire
CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire
PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan
Advertisement
UsernamePublicRestriction

Register

PS040756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel